SHERP

Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment

Cited 0 time in webofscience Cited 54 time in scopus
Authors
Han, Sae-Won; Kim, Hwang-Phill; Jeon, Yoon Kyung; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Chung, Doo Hyun; Heo, Dae Seog; Bang, Yung-Jue; Kim, Tae-You
Issue Date
2008-01-14
Publisher
Elsevier
Citation
Lung Cancer 2008;61:30-34
Keywords
Mucoepidermoid carcinomaEGFRMutationGefitinibLung cancerL858R
Abstract
Mucoepidermoid carcinoma (MEC) of lung is a rare malignancy of lung which originates from minor salivary glands of tracheobronchial tree. EGFR targeted therapy by inhibition of EGFR activation with the specific tyrosine kinase inhibitors (TKIs) has shown meaningful anti-tumor activity in patients with EGFR TK mutation and/or amplification, or in patients with adenocarcinoma. In the present study, we find that MEC has EGFR mutation in 40% (2 out of 5) of cases, and all mutations are L858R mutation. In addition, we also observed that a MEC patient well-responded to EGFR TKI in the absence of EGFR mutation or amplification. These data indicate for the first time that MEC of lung is another potential target of EGFR inhibitor, and more extended clinical investigation is warranted.
ISSN
0169-5002 (print)
1872-8332 (online)
Language
English
URI
http://hdl.handle.net/10371/3705
DOI
https://doi.org/10.1016/j.lungcan.2007.11.014

https://doi.org/10.1016/j.lungcan.2007.11.014
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pathology (병리학전공)Journal Papers (저널논문_병리학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse